ClinicalTrials.gg
CompletedNCT00214500Updated Oct 30, 2018Results posted

A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

A Phase 2 interventional study of migalastat HCl in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 5 sites in United States. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
16th of 20
9 · median 20
Started
2006
with 3 others
Phase 2
6 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 16th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 2, and was the 1st registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.

Read the detailed description

This was a Phase 2, open-label study in male participants with Fabry disease. All participants who met initial eligibility criteria underwent a 28-day screening period, including a 14-day run-in with migalastat (150 milligrams [mg] migalastat once a day [QD] from Days -28 to -15) to assess eligibility for entering the treatment period of the study. Participants who entered the treatment period were required to have α-galactosidase A (α-Gal A) activity responsive to migalastat.

Fifteen participants received at least 1 dose of study drug, however, 6 of these participants did not demonstrate α-Gal A activity responsive to migalastat and were thus screen failures (these participants are hereafter referred to as "dosed screen failures") due to not meeting all inclusion criteria for treatment. Therefore, 9 participants were enrolled into the treatment period (these participants are hereafter referred to as "eligible-enrolled").

Eligible-enrolled participants (those who satisfied the criteria for inclusion in the study) received escalating doses of migalastat twice a day (BID) for 6 weeks (Days 1 to 42), followed by 6 weeks at 1 dose level BID (Days 43 to 84) during the treatment period. Participants could then opt to participate in the extension period. The study consisted of 2 optional extension periods, the first through Week 48 and the second through Week 96. For participants who did not continue into the optional treatment extension, the study included a 2-week follow-up period.

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Amicus Therapeutics
  • AT1001
  • Galafold
  • Migalastat
  • Substrate
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males between 18 and 55 years of age (inclusive)
  • Hemizygous for Fabry disease
  • Had a confirmed diagnosis of Fabry disease with a documented missense gene mutation (individual or familial)
  • Had enhanceable enzyme activity
  • In the judgment of the investigator, were either able to safely suspend ERT throughout the study, or be ERT naive
  • Agreed to be sexually abstinent or use a condom with spermicide when engaging in sexual activity during the course of the study and for a period of 30 days following completion of the study
  • Were willing and able to sign an form

Exclusion criteria

Exclusion Criteria:

  • History of significant disease other than Fabry disease (for example, end-stage renal disease; Class III or IV heart disease [per the classification]; current diagnosis of cancer, except for basal cell carcinoma of the skin; diabetes [unless ≤8]; or neurological disease that would have impaired the participant's ability to participate in the study)
  • History of organ transplant
  • Serum creatinine >2 mg per deciliter on Day -2
  • Screening 12-lead demonstrating interval >450 milliseconds prior to dosing
  • Taking a medication prohibited by the protocol: Fabrazyme® (agalsidase beta), Replagal™ (agalsidase alfa), Glyset® (miglitol), Zavesca® (miglustat), or any experimental therapy for any indication
  • Participated in a previous clinical trial in the last 30 days
  • Any other condition, which, in the opinion of the investigator, would jeopardize the safety of the participant or impact the validity of the study results
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Migalastat

    Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods. Treatment Period: * Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14). * Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28). * Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42). * Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84). Extension Period: * Migalastat 25 mg BID for Weeks 12 through 48. * Migalastat 50 mg QD for Weeks 48 through 96.

    Drug: migalastat HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 96 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Day 1 (after dosing) through Week 96

Secondary outcomes

  1. PK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat

    The AUC from time zero to 12 hours (hr) postdose (AUC0-12) was evaluated in plasma following a single dose of migalastat 25, 100, and 250 mg on Days 1, 15, and 29, respectively. In addition, AUC0-12 was assessed following multiple doses (14 days) of migalastat 25, 100, and 250 mg on Days 14, 28, and 42, respectively.

    Time frame: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hr (postdose)

  2. α-Galactosidase A (α-Gal A) Activity In Leukocytes At Baseline, Week 12, And Week 96

    Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.

    Time frame: Baseline, Week 12 (end of treatment period), Week 96 (end of extension period)

07

Results

Posted Sep 7, 2018

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneMigalastat
Started9
Safety population9
Pharmacokinetic (pk) population9
Pharmacodynamic (pd) population9
Completed8
Not completed1
Withdrew: Adverse event1
Extension Period
Participant flow — Extension Period
MilestoneMigalastat
Started8
Completed6
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 96 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Day 1 (after dosing) through Week 96
Reported as:
Count of participants · Participants
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)
ParticipantsMigalastat
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)2
SecondaryPK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat

The AUC from time zero to 12 hours (hr) postdose (AUC0-12) was evaluated in plasma following a single dose of migalastat 25, 100, and 250 mg on Days 1, 15, and 29, respectively. In addition, AUC0-12 was assessed following multiple doses (14 days) of migalastat 25, 100, and 250 mg on Days 14, 28, and 42, respectively.

Time frame:
0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hr (postdose)
Reported as:
Geometric mean · nanograms*hr/milliliters (ng*hr/mL)
PK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat
nanograms*hr/milliliters (ng*hr/mL)Migalastat 25 mgMigalastat 100 mgMigalastat 250 mg
AUC0-12: Single Dose1052.96 ± 29.94217.95 ± 32.010880.66 ± 32.4
AUC0-12: Multiple Dose1360.69 ± 32.95643.50 ± 25.312244.47 ± 26.0
Secondaryα-Galactosidase A (α-Gal A) Activity In Leukocytes At Baseline, Week 12, And Week 96

Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.

Time frame:
Baseline, Week 12 (end of treatment period), Week 96 (end of extension period)
Reported as:
Number · nmol 4-MU/hr/mg protein
α-Galactosidase A (α-Gal A) Activity In Leukocytes At Baseline, Week 12, And Week 96
nmol 4-MU/hr/mg proteinMigalastat
Participant 1: Baseline5.2
Participant 1: Week 1217.4
Participant 1: Week 9620.3
Participant 2: Baseline4.7
Participant 2: Week 1224.6
Participant 2: Week 9622.8
Participant 3: Baseline6.6
Participant 3: Week 1224.6
Participant 3: Week 9620.3
Participant 4: Baseline1.0
Participant 4: Week 1214.8
Participant 4: Week 9612.8
Participant 5: Baseline10.7
Participant 6: Baseline0.9
Participant 6: Week 123.9
Participant 6: Week 961.9
Participant 7: Baseline0.0
Participant 7: Week 120.4
Participant 8: Baseline0.1
Participant 8: Week 120.9
Participant 9: Baseline0.2
Participant 9: Week 120.3
Participant 9: Week 960.2

Adverse events

Collected over Day 1 after dosing through Week 96 (end of extension period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat—0/9 (0%)9/9 (100%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventMigalastat
HeadacheNervous system disorders5/9
NauseaGastrointestinal disorders4/9
Abdominal pain upperGastrointestinal disorders2/9
Back painMusculoskeletal and connective tissue disorders2/9
DiarrhoeaGastrointestinal disorders2/9
Dry mouthGastrointestinal disorders2/9
InsomniaPsychiatric disorders2/9
MyalgiaMusculoskeletal and connective tissue disorders2/9
PainGeneral disorders2/9
Pain in extremityMusculoskeletal and connective tissue disorders2/9

Baseline characteristics

Eligible-enrolled participants who received at least 1 dose of study drug. 6 participants were dosed screen failures, and were not included in safety, PK, or PD analyses.

Age, Continuous
Age, Continuous(years)Migalastat
Mean36.7 ± 13.0
Age, Customized
Age, Customized(Participants)Migalastat
17 years1
18 to 55 years7
58 years1
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat
Female0
Male9
08

Study locations

5 sites
  • Los Angeles, California 90048, United States
  • Decatur, Georgia 30033, United States
  • Bethesda, Maryland 20892, United States
  • New York, New York 10016, United States
  • Houston, Texas 77030, United States
09

References and documents

Publications

  • Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22. PubMed 27657681 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Jan 2008, 24 months.

Results were first posted in Sep 2018, 10 years 7 months after primary completion. A results delay was requested in Aug 2010.

Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
StartActual
Jan 2, 2006
Primary completionActual
Jan 29, 2008
CompletionActual
Jan 29, 2008
Results delay requested
Aug 17, 2010
Results first posted
Sep 7, 2018
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00214500
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Jan 2, 2006
Primary completion
Jan 29, 2008
Completion
Jan 29, 2008
Results posted
Sep 7, 2018
Last update
Oct 30, 2018

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion